Biomarkers and methods for determining efficacy of anti-EGFR antibodies in cancer therapy

Details for Australian Patent Application No. 2010262133 (hide)

Owner Merck Patent GmbH

Inventors Stroh, Christopher; Von Heydebreck, Anja

Agent Davies Collison Cave

Pub. Number AU-A-2010262133

PCT Pub. Number WO2010/145796

Priority 09012197.1 25.09.09 EP; 09008042.5 19.06.09 EP

Filing date 15 June 2010

Wipo publication date 23 December 2010

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

2 February 2012 PCT application entered the National Phase

  PCT publication WO2010/145796 Priority application(s): WO2010/145796

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010262139-A monolithic, side pumped solid-state laser and applications thereof

2010262130-Bispecific, tetravalent antigen binding proteins